Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 27;13(1):1891852. doi: 10.1080/19490976.2021.1891852

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — I-FABP concentrations pre- and post ETEC challenge

A. Magnitudes and kinetics of MPO based on clinical outcome following ETEC challenge with 10⁶/10⁷ dose. MSD: moderate to severe diarrhea; ND: no diarrhea; D0: day before challenge; 1 to 9: 1 to 9 days after challenge. B. Comparison of the pre- and post-challenged peak I-FABP concentrations on any day by clinical outcome. D0: day before challenge; Peak: highest concentrations of MPO any day; MSD: moderate to severe diarrhea; ND: no diarrhea; Box plot showing Min, Max and Median. p < .05:*; p < .01:**. Rx: Antibiotic treatment.